Researchers at the University of Arizona examined statistics from the National Cancer Database from 2010 to 2017, focusing on stage II pancreatic cancer patients with positive margins. They compared patients who had R1/R2 surgery after neoadjuvant chemotherapy with those who had surgery only, those who had surgery before chemotherapy and patients who only received chemotherapy. Read more . . .
Surgical oncologists can extend the lives of patients with stage II pancreatic cancer by taking an aggressive multimodality treatment approach and opting for neoadjuvant chemotherapy followed by resection, according to a recent study (J Am Coll Surg 2021 Mar 26. doi:10.1016/j.jamcollsurg.2021.02.020).